Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / COMMON STOCK, $0.001 PAR VALUE PER SHARE
-
Shares outstanding
-
1.64M
-
Number of holders
-
25
-
Total 13F shares, excl. options
-
1.19M
-
Shares change
-
+364K
-
Total reported value, excl. options
-
$3.58M
-
Value change
-
+$1.04M
-
Put/Call ratio
-
2.41
-
Number of buys
-
17
-
Number of sells
-
-5
-
Price
-
$3.01
Significant Holders of QUALIGEN THERAPEUTICS, INC. - COMMON STOCK, $0.001 PAR VALUE PER SHARE (QLGN) as of Q4 2020
30 filings reported holding QLGN - QUALIGEN THERAPEUTICS, INC. - COMMON STOCK, $0.001 PAR VALUE PER SHARE as of Q4 2020.
QUALIGEN THERAPEUTICS, INC. - COMMON STOCK, $0.001 PAR VALUE PER SHARE (QLGN) has 25 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.19M shares
of 1.64M outstanding shares and own 72.62% of the company stock.
Largest 10 shareholders include BlackRock Inc. (318K shares), VANGUARD GROUP INC (301K shares), GEODE CAPITAL MANAGEMENT, LLC (123K shares), QS Investors, LLC (82K shares), SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC (62.5K shares), CITADEL ADVISORS LLC (45.9K shares), Cetera Investment Advisers (40.3K shares), NORTHERN TRUST CORP (38.7K shares), WEDBUSH SECURITIES INC (32.2K shares), and WELLS FARGO & COMPANY/MN (30.5K shares).
This table shows the top 25 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.